Authors : Abhishek Shrivastava, Dheerendra Kumar Sachan, Ruchita Sachan, Varsha Mandloi
DOI : 10.18231/j.jdpo.2020.002
Volume : 5
Issue : 1
Year : 2020
Page No : 9-12
Introduction: Triple negative breast cancer (TNBC) is diagnosed more frequently in younger and
premenopausal women. TNBC are biologically aggressive tumours, not benefited from hormonal or
targeted therapy although some reports suggest that they respond well to chemotherapy. The aim of our
study is was to assess the response of anthracyclines based adjuvant chemotherapy in triple negative breast
cancer.
Materials and Methods: This is was a retrospective study conducted on 100 post-operative patients,
histopathologically proven ductal Carcinoma Breast, from January 2016 to March 2017 presenting to
tertiary care centre. All patients were triple negative as assessed by immunohistochemistry and fluorescence
in situ hybridization technique. Patients were planned for six cycles of Anthracycine based combination
adjuvant chemotherapy. Data were analyzed by SPSS 20 and survival analysis was done.
Results: A total of 100 patients were included in this study. Out of these,18patients (18%) were defaulted
after chemotherapy, 29 patients (29%) were lost during subsequent follow ups and 49 patients (49%) had
disease free survival (DFS) and 4 patients (4%) survived with bone metastasis. The median survival was
18 months, disease free survival was 7.8 months and 3 year overall survival (OS) was 18.6 months.
Conclusions: TNBC represent a challenge for the patients and the clinician due to its poor prognosis and
fewer treatment options. The adjuvant Anthracycline -based combination chemotherapy predict improved
long term outcomes for TNBC.
Keywords: TNBC, Survival analysis, Anthracycline based chemotherapy